{
    "question_id": "timing_q3_par",
    "context": [
        {
            "id": 0,
            "source": "中国年龄相关性黄斑变性临床诊疗指南（2023年）",
            "content": "Corresponding author: Xu Xun, Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, National Clinical Research Center for Eye Diseases, Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai Engineering Center for Precise Diagnosis and Treatment of Eye Diseases, Shanghai 200080, China, Email: drxuxun@tom.com\n\n【Abstract】 Age‑related macular degeneration (AMD) is the main cause of low vision and even blindness in the elderly. With the aging of our population, the number of AMD patients will continue to rise. In the past decade, the rapid development of ocular fundus imaging technology has provided a new perspective and approach for the classification, diagnosis and follow‑up of AMD. The advent of new drugs has provided more diverse intervention and treatment methods for AMD, especially for neovascular AMD, and the emphasis on accurate and individualized treatment has put forward higher requirements for retinal specialists. Therefore, based on the latest evidence‑based medical information, combined with the international guidelines and the current situation of China′s social and economic development, experts from the Chinese Vitreo‑Retinal Society of Chinese Medical Association, the Fundus Disease Group of Chinese Ophthalmologist Association, and the\n\nNational Clinical Research Center for Eye Diseases gave recommendations around eight clinical problems and formed China′s guidelines for the clinical diagnosis and treatment of AMD. With the implementation of these guidelines, we can standardize the diagnosis, treatment, prevention and follow‑up of AMD in China. (This article was published ahead of print on the official website of Chinese Journal of Ophthalmology on April 6, 2023)\n\n【Key words】 Macular degeneration; Practice guidelines as topic; Evidence‑based medicine\n\nPractice guideline registration: Practice Guideline Registration for Transparency, IPGRD‑2021CN111\n\n年 龄 相 关 性 黄 斑 变 性（age‑related maculardegeneration，AMD）是老年人群低视力乃至失明的主要原因［1］ ，2040年全球AMD患者数量预计将达到 2.88 亿例［2‑3］ 。我国 70 岁以上人群 AMD 的患病率为 $2 0 . 2 \\% ^ { [ 3 ] }$ ，随着我国人口老龄化的加剧，AMD的患者数量也在持续上升。\n\n2013 年国际 Beckmann AMD 分类研究小组根据临床表现，将 分为无明显年龄性改变、正常年 龄 性 改 变 、早 期 AMD、中 期 AMD 和 进 展 期$\\mathrm { A M D } ^ { [ 4 ] }$ 。 年 龄 相 关 性 眼 病 研 究（Age‑related Eye， ）小组的 分期标准与Beckmann分期类似［5］ 。进展期AMD又分为地图样萎缩（geographic atrophy，GA）和新生血管性 AMD，新生血管性AMD也称为渗出性或湿性AMD，占AMD 的 $1 0 \\% { \\sim } 2 0 \\% ^ { [ 1 ] }$ 。随着相干光层析成像术（optical coherence tomography，OCT）的应用和 AMD研究深入，国际AMD命名共识研究组于2020年更新了新生血管性 AMD 黄斑区新生血管（macularneovascularization，MNV）的分型，根据 OCT 图像中MNV的起源和位置，将其分为1、2和3型［6］。"
        },
        {
            "id": 1,
            "source": "和血明目片治疗湿性年龄相关性黄斑变性临床应用专家共识 ",
            "content": "芎组成，具有凉血止血、滋阴化瘀、养肝明目的作用，用于阴虚肝旺，热伤络脉所引起的眼底出血。\n\n年龄相关性黄斑变性（age-related macular degeneration, AMD）是一种随年龄增加而发病率增高并导致中心视力下降的黄斑区视网膜组织退行性病变，尤其是湿性年龄相关性黄斑变性(wet age-related macular degeneration, wAMD)严重损害视力，影响日常生活和工作，致盲率高，给患者家庭和社会带来严重的经济负担[4]。随着人口年龄结构的老化，AMD发病率有逐年增高的趋势：50~59岁  $5.7\\%$  ，60~69岁\n\n13.9%, 70岁以上20.9%, 80岁以上23.5%。伴随患病率的不断上升, 该疾病已成为我国老年人群不可逆视力损伤的主要原因[5]。和血明目片作为纯中药制剂, 在治疗wAMD时有较好的临床疗效, 对wAMD所致的黄斑水肿、视网膜出血等症状有明显的改善作用, 同时能够缩短患者病程、改善视功能,在《中成药治疗年龄相关性黄斑变性(湿性)临床应用指南》中作为治疗药物推荐使用。"
        },
        {
            "id": 2,
            "source": "中国眼底OCT操作及图像阅读报告规范德尔菲法专家共识（2025年） ",
            "content": "### （五）病理性近视眼黄斑病变（pathological myopia macular degeneration, PMMD）\n\n病理性近视眼的眼球后极部扩张，视盘和巩膜管口受到不同方向力的牵拉，发生一系列特征性形态改变，如视盘倾斜和旋转、视杯变浅、盘沿不规则、视盘周围脉络膜和视网膜萎缩等。OCT图像表现为ERM、神经视网膜劈裂、黄斑裂孔、SHRM、\n\n视盘旁脉络膜空腔(peripapillary intrachoroidal cavitation, PICC)及圆顶状黄斑（dome-shaped macula, DSM)等。PICC表现为视盘旁脉络膜内液性空腔, DSM表现为后巩膜葡萄肿凹陷处黄斑区向内隆起[81-83]。\n\n推荐意见18：DME的OCT图像表现为黄斑视网膜反射增厚、视网膜内积液和(或)SRF、神经视网膜层间高反射点、DRIL、外界膜和(或)椭圆体区连续性中断等，可伴有玻璃体视网膜界面异常。RVO黄斑水肿的OCT图像也可表现为黄斑神经视网膜反射增厚、视网膜内积液和(或)SRF、神经视网膜层间高反射点等，也可伴有玻璃体视网膜界面异常。早中期AMD的OCT图像表现为RPE不规则隆起，未累及黄斑中心凹的外层视网膜和RPE萎缩变薄；进展期AMD表现为累及黄斑中心凹的外层视网膜和RPE萎缩变薄，神经视网膜下和(或)RPE下中高反射(MNV、出血等)，伴有视网膜内积液和(或)SRF，各种类型的RPE下积液。CSC的OCT图像表现为SRF、可伴有RPE下积液、脉络膜增厚、脉络膜中大血管扩张。PMMD的OCT图像表现为ERM、神经视网膜劈裂、黄斑裂孔、SHRM、PICC、DSM和视网膜脉络膜萎缩变薄等改变(GPS)。"
        }
    ],
    "query_top_k": 10,
    "rerank_top_n": 3,
    "query": "Symptoms of macular degeneration?",
    "index_name": "md-medical-guide-faiss-chunks",
    "rerank_model": "bm25",
    "embed_model": "openai:text-embedding-3-small"
}